Is Takeda Pharmaceutical Stock a Good Investment?
Takeda Pharmaceutical Investment Advice | TAK |
- Examine Takeda Pharmaceutical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Takeda Pharmaceutical's leadership team and their track record. Good management can help Takeda Pharmaceutical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Takeda Pharmaceutical's business and its evolving consumer preferences.
- Compare Takeda Pharmaceutical's performance and market position to its competitors. Analyze how Takeda Pharmaceutical is positioned in terms of product offerings, innovation, and market share.
- Check if Takeda Pharmaceutical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Takeda Pharmaceutical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Takeda Pharmaceutical Co stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Takeda Pharmaceutical Co is a good investment.
Sell | Buy |
Strong Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Takeda Pharmaceutical Stock
Researching Takeda Pharmaceutical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.86. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Takeda Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.7. The entity last dividend was issued on the 27th of March 2024.
To determine if Takeda Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Takeda Pharmaceutical's research are outlined below:
| Takeda Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Latest headline from benzinga.com: Insights Into Johnson Johnsons Performance Versus Peers In Pharmaceuticals Sector |
Takeda Pharmaceutical Quarterly Liabilities And Stockholders Equity |
|
Takeda Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Takeda Pharmaceutical Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Takeda Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Takeda Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Takeda Pharmaceutical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.0142 | -0.0065 | 0.0077 | 54 | ||
2023-05-22 | 2023-03-31 | 0.0505 | 0.074 | 0.0235 | 46 | ||
2022-10-27 | 2022-09-30 | 0.1757 | 0.1345 | -0.0412 | 23 | ||
2018-10-31 | 2018-09-30 | 0.23 | 0.2736 | 0.0436 | 18 | ||
2018-05-14 | 2018-03-31 | -0.37 | -0.3142 | 0.0558 | 15 | ||
2021-02-04 | 2020-12-31 | 0.4536 | 0.3968 | -0.0568 | 12 | ||
2022-02-03 | 2021-12-31 | 0.2205 | 0.1605 | -0.06 | 27 | ||
2023-07-27 | 2023-06-30 | 0.1208 | 0.2049 | 0.0841 | 69 |
Know Takeda Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Takeda Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Takeda Pharmaceutical Co backward and forwards among themselves. Takeda Pharmaceutical's institutional investor refers to the entity that pools money to purchase Takeda Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-06-30 | 1.6 M | Envestnet Asset Management Inc | 2024-06-30 | 1.5 M | Blackrock Inc | 2024-06-30 | 1.4 M | Causeway Capital Management Llc | 2024-06-30 | 1.4 M | Macquarie Group Ltd | 2024-06-30 | 1 M | Wells Fargo & Co | 2024-06-30 | 871.7 K | Bank Of America Corp | 2024-06-30 | 867.1 K | Jane Street Group, Llc | 2024-06-30 | 603.8 K | Kayne Anderson Rudnick Investment Management Llc | 2024-06-30 | 585.8 K | Capital Research Global Investors | 2024-06-30 | 13.1 M | Mondrian Investment Partners Ltd | 2024-06-30 | 7.7 M |
Takeda Pharmaceutical's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 45.36 B.Market Cap |
|
Takeda Pharmaceutical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Determining Takeda Pharmaceutical's profitability involves analyzing its financial statements and using various financial metrics to determine if Takeda Pharmaceutical is a good buy. For example, gross profit margin measures Takeda Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Takeda Pharmaceutical's profitability and make more informed investment decisions.
Evaluate Takeda Pharmaceutical's management efficiency
Takeda Pharmaceutical has Return on Asset of 0.0205 % which means that on every $100 spent on assets, it made $0.0205 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0204 %, implying that it generated $0.0204 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.03. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 15.9 T this year, although the value of Non Current Liabilities Other will most likely fall to about 435.2 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.6 K | 4.9 K | |
| Tangible Book Value Per Share | -1.5 K | -1.5 K | |
| Enterprise Value Over EBITDA | 6.78 | 11.61 | |
| Price Book Value Ratio | 0.45 | 0.42 | |
| Enterprise Value Multiple | 6.78 | 11.61 | |
| Price Fair Value | 0.45 | 0.42 | |
| Enterprise Value | 6.5 T | 3.8 T |
The analysis of Takeda Pharmaceutical's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Takeda Pharmaceutical's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Takeda Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield 0.0409 | Forward Dividend Yield 0.0409 | Forward Dividend Rate 0.58 | Beta 0.498 |
Basic technical analysis of Takeda Stock
As of the 11th of October 2024, Takeda Pharmaceutical has the Semi Deviation of 0.9855, coefficient of variation of 934.53, and Risk Adjusted Performance of 0.0908. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Takeda Pharmaceutical, as well as the relationship between them.Takeda Pharmaceutical's Outstanding Corporate Bonds
Takeda Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Takeda Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Takeda bonds can be classified according to their maturity, which is the date when Takeda Pharmaceutical Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TTWO 355 14 APR 25 Corp BondUS874054AF63 | View | |
| TTWO 37 14 APR 27 Corp BondUS874054AG47 | View | |
| TTWO 4 14 APR 32 Corp BondUS874054AH20 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AW64 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AX48 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AY21 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AZ95 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060BD74 | View |
Understand Takeda Pharmaceutical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Takeda Pharmaceutical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0908 | |||
| Market Risk Adjusted Performance | 0.3633 | |||
| Mean Deviation | 0.8408 | |||
| Semi Deviation | 0.9855 | |||
| Downside Deviation | 1.14 | |||
| Coefficient Of Variation | 934.53 | |||
| Standard Deviation | 1.15 | |||
| Variance | 1.33 | |||
| Information Ratio | 0.0165 | |||
| Jensen Alpha | 0.083 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0167 | |||
| Treynor Ratio | 0.3533 | |||
| Maximum Drawdown | 6.7 | |||
| Value At Risk | (1.72) | |||
| Potential Upside | 1.68 | |||
| Downside Variance | 1.29 | |||
| Semi Variance | 0.9712 | |||
| Expected Short fall | (0.94) | |||
| Skewness | 0.0055 | |||
| Kurtosis | 2.3 |
| Risk Adjusted Performance | 0.0908 | |||
| Market Risk Adjusted Performance | 0.3633 | |||
| Mean Deviation | 0.8408 | |||
| Semi Deviation | 0.9855 | |||
| Downside Deviation | 1.14 | |||
| Coefficient Of Variation | 934.53 | |||
| Standard Deviation | 1.15 | |||
| Variance | 1.33 | |||
| Information Ratio | 0.0165 | |||
| Jensen Alpha | 0.083 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0167 | |||
| Treynor Ratio | 0.3533 | |||
| Maximum Drawdown | 6.7 | |||
| Value At Risk | (1.72) | |||
| Potential Upside | 1.68 | |||
| Downside Variance | 1.29 | |||
| Semi Variance | 0.9712 | |||
| Expected Short fall | (0.94) | |||
| Skewness | 0.0055 | |||
| Kurtosis | 2.3 |
Consider Takeda Pharmaceutical's intraday indicators
Takeda Pharmaceutical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Takeda Pharmaceutical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 44110.3 | |||
| Daily Balance Of Power | (0.05) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 14.21 | |||
| Day Typical Price | 14.24 | |||
| Price Action Indicator | 0.085 | |||
| Period Momentum Indicator | (0.01) |
Takeda Pharmaceutical Corporate Filings
6K | 26th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
FWP | 28th of June 2024 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
| 27th of June 2024 Other Reports | ViewVerify | |
| 25th of April 2024 Other Reports | ViewVerify |
Takeda Stock media impact
Far too much social signal, news, headlines, and media speculation about Takeda Pharmaceutical that are available to investors today. That information is available publicly through Takeda media outlets and privately through word of mouth or via Takeda internal channels. However, regardless of the origin, that massive amount of Takeda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Takeda Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Takeda Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Takeda Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Takeda Pharmaceutical alpha.
Takeda Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Takeda Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Takeda Pharmaceutical Historical Investor Sentiment
Investor biases related to Takeda Pharmaceutical's public news can be used to forecast risks associated with an investment in Takeda. The trend in average sentiment can be used to explain how an investor holding Takeda can time the market purely based on public headlines and social activities around Takeda Pharmaceutical Co. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Takeda Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Takeda Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Takeda Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Takeda Pharmaceutical.
Takeda Pharmaceutical Corporate Directors
| JeanLuc Butel | Independent Director | Profile | |
| Michel Orsinger | Independent Director | Profile | |
| Shiro Kuniya | Independent Director | Profile | |
| Toshiyuki Shiga | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 188 | Earnings Share 0.32 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.141 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Takeda Pharmaceutical's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.